347 related articles for article (PubMed ID: 17644541)
1. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.
Kavanaugh A; Rosengren S; Lee SJ; Hammaker D; Firestein GS; Kalunian K; Wei N; Boyle DL
Ann Rheum Dis; 2008 Mar; 67(3):402-8. PubMed ID: 17644541
[TBL] [Abstract][Full Text] [Related]
2. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
Thurlings RM; Vos K; Wijbrandts CA; Zwinderman AH; Gerlag DM; Tak PP
Ann Rheum Dis; 2008 Jul; 67(7):917-25. PubMed ID: 17965121
[TBL] [Abstract][Full Text] [Related]
3. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
4. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Edwards JC; Szczepanski L; Szechinski J; Filipowicz-Sosnowska A; Emery P; Close DR; Stevens RM; Shaw T
N Engl J Med; 2004 Jun; 350(25):2572-81. PubMed ID: 15201414
[TBL] [Abstract][Full Text] [Related]
6. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.
Toubi E; Kessel A; Slobodin G; Boulman N; Pavlotzky E; Zisman D; Rozenbaum M; Rosner I
Ann Rheum Dis; 2007 Jun; 66(6):818-20. PubMed ID: 17148544
[TBL] [Abstract][Full Text] [Related]
7. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
9. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B
Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
12. B cells in rheumatoid arthritis: from hypothesis to the clinic.
Keystone EC
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii8-ii12. PubMed ID: 15851525
[TBL] [Abstract][Full Text] [Related]
13. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
16. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab.
Rosengren S; Wei N; Kalunian KC; Zvaifler NJ; Kavanaugh A; Boyle DL
Arthritis Res Ther; 2008; 10(5):R105. PubMed ID: 18761748
[TBL] [Abstract][Full Text] [Related]
17. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
18. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
20. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
